Investigators sought to evaluate changes in the estimated CV risk of men with prostate cancer after 6 months of hormone therapy using clinical tools established for the general population.

Stage 3 prostate cancer is locally advanced, with tumors extending beyond the prostate but not metastasizing distantly.

The FDA approved niraparib and abiraterone acetate (Akeega) in combination with prednisone for treating BRCA2 -mutated ...

The U.S. Food and Drug Administration (FDA) has approved niraparib (Zejula) plus Akeega (abiraterone acetate) and prednisone ...

WASHINGTON — Former President Joe Biden is receiving radiation and hormone therapy as part of a new phase of treating the aggressive form of prostate cancer he was diagnosed with after leaving office, ...

Dr. Matthew Smith answers the question: 'Hormone Refractory Prostate Cancer?' March 16, 2009 -- Question: What is hormone refractory prostate cancer? Answer: Nearly all men respond to initial ...

This recent analysis found that, despite similar clinical outcomes, genomic differences were observed in mCRPC differences by race, highlighting the importance of racial diversity in future genomic ...

If you have prostate cancer, your health care provider may have told you about a medicine called Nubeqa (darolutamide). The FDA approved Nubeqa in 2019. It is commonly used to treat prostate cancer ...

A growing array of pharmaceutical options has investigators trying to figure out which drugs and drug combinations are the best to prescribe upfront—and to which patients. Over the past 14 years, ...

This satellite symposium at the European Society for Medical Oncology (ESMO) Congress 2025, chaired by Rana McKay, Professor ...